BPC-157

At a glance

What is BPC-157?

BPC-157 stands for Body Protection Compound-157. It's a synthetic peptide — a short chain of 15 amino acids — derived from a larger protective protein found naturally in human gastric (stomach) juice.^[1]

The compound was first described in the early 1990s by a research group led by Predrag Sikiric at the University of Zagreb, Croatia. They observed that gastric juice proteins seemed to protect the stomach lining, and isolated a specific 15-amino-acid fragment that appeared to retain many of those protective properties.

It's important to understand what "derived from gastric juice" means: BPC-157 is not extracted from your stomach. It's a synthetic fragment that shares a sequence with part of a naturally occurring protein. The peptide itself does not exist in isolation in the human body — it's manufactured in a laboratory.

The name "Body Protection Compound" reflects the broad protective effects observed in animal models, where the peptide has been studied for everything from stomach ulcers to tendon injuries to nerve damage. This breadth of effects is both the compound's appeal and a source of scientific skepticism — most drugs do one thing well, not everything.

How it works

In plain terms, BPC-157 appears to accelerate the body's natural healing processes. It promotes the growth of new blood vessels, reduces inflammation, and stimulates production of growth factors involved in tissue repair.^[4]

Think of it as a peptide that seems to "turn up the volume" on repair signals your body already uses — based on what we've observed in animal studies.

What the research says

Despite more than one hundred animal studies demonstrating healing effects across multiple organ systems, BPC-157 has never completed a Phase II or Phase III human clinical trial — the most significant gap in its evidence profile.

Research timeline

Over three decades of research, BPC-157 has accumulated extensive animal data — but the human evidence trail is remarkably thin:

Human clinical trials

The entire body of published human evidence for BPC-157 consists of three small studies with a combined total of approximately 30 participants. Here's what each found:

All three of these studies share the same lead author (Edwin Lee, Institute for Hormonal Balance, Orlando, FL) and were published in the same journal (Alternative Therapies in Health and Medicine). There is also one registered trial on ClinicalTrials.gov — NCT02637284, a Phase I safety study originally planned for 42 healthy volunteers. It was effectively cancelled, and no results were ever published.^[13]

Animal studies

The preclinical literature is vast — over 100 published studies — but carries an important caveat: the overwhelming majority come from a single laboratory (Sikiric et al. at the University of Zagreb). Independent replication is extremely limited.^[9]

What the evidence shows

People come to BPC-157 with specific questions. Here's what the published research actually tells us about the most common areas of interest:

Safety & side effects

What research shows

In preclinical studies, BPC-157 has a remarkably clean toxicology profile. Researchers could not establish a lethal dose in mice, rats, rabbits, or dogs. No mutagenic or genotoxic effects were found in vitro.^[10]

The only controlled human safety data comes from a 2025 dose-escalation study in 2 subjects, where intravenous doses up to 20 mg produced no adverse events.^[8]

Community-reported side effects

Among people who have used BPC-157 outside of clinical settings, commonly reported effects include:

• Injection-site redness, swelling, or tenderness
• Mild nausea (more common with oral use)
• Temporary fatigue
• Headache
• Mild dizziness
• Rare: skin rash or allergic reaction

These are self-reported and not from controlled studies. They should be taken as signal, not as definitive safety data.

Theoretical risks

How people use it

BPC-157 is most commonly discussed in the context of injury recovery and gut health. Here's what the landscape of use looks like — with important caveats.

Administration routes

• Subcutaneous injection (most common): Injected near the site of injury for local effects, or in the abdomen for systemic effects.
• Oral capsule: Some practitioners use oral BPC-157, citing animal data suggesting gastric stability. No human pharmacokinetic data confirms oral bioavailability.
• Intramuscular: Less common, used for deeper tissue injuries.
• Intranasal: Emerging use for potential CNS effects. No clinical data.

Common stacking context

In community practice, BPC-157 is often discussed alongside other peptides:

• BPC-157 + TB-500 — sometimes called the "Wolverine stack," this combination targets healing through complementary mechanisms (angiogenesis + actin regulation). No clinical data supports this combination.
• BPC-157 + GHK-Cu — a tissue repair pairing. Anecdotal reports only.
• BPC-157 + KPV — discussed for gut inflammation. No controlled studies.

All stacking protocols are community-derived and have not been studied in any controlled setting.

If you plan to reconstitute peptides, see our reconstitution guide for safety-first preparation instructions.

Legal & regulatory status

As of March 2026:

FDA status

BPC-157 is not FDA-approved for any indication. In September 2023, the FDA classified it as a Category 2 bulk drug substance — meaning the agency determined there was insufficient evidence that it is safe for human use. Under this classification, compounding pharmacies are prohibited from using it.^[14]

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 Category 2 peptides would be reclassified to Category 1, restoring legal compounding access with a physician prescription. BPC-157 is expected to be among those reclassified.

WADA / USADA status

BPC-157 has been prohibited at all times under WADA Section S0 (Non-Approved Substances) since 2022. It is not eligible for a Therapeutic Use Exemption (TUE). Athletes testing positive face a standard 4-year ban.^[15]

International status

BPC-157 is not approved for clinical use in any country. It is available as a "research chemical" in most jurisdictions and is sold in supplement and peptide form online without regulatory approval.

How BPC-157 compares

To put BPC-157's evidence base in context, here's how it compares to a well-studied peptide drug:

The contrast is instructive. Semaglutide went through the full FDA approval process — thousands of participants, multi-year trials, extensive safety monitoring. BPC-157 has been studied for 30+ years with over 100 publications, yet the human evidence base would barely fill a single pilot study.

This doesn't mean BPC-157 doesn't work. It means we don't yet have the data to know with confidence.